BLUHM CARDIOVASCULAR INSTITUTE

Transcatheter Heart Valve Therapies for the Mitral Valve

As one of the highest volume and most experienced transcatheter mitral valve programs in the nation, Northwestern Medicine continues to expand its Transcatheter Heart Valve Program by offering a wide array of commercially available and clinical trial options to treat the mitral valve, including MitraClip.

LEARN MORE

312.NM.HEART (312.664.3278) | heart.nm.org | Inquiries: BCVI_info@nm.org

All Rights Reserved. ©2019 by Northwestern Medicine® and Northwestern Memorial HealthCare. 

Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University.

Northwestern Medicine ® | 251 E Huron Street | Chicago, IL 60611 | nm.org

Charles J. Davidson, MD 
Interventional Cardiology
Commercially Available – Mitral Valve: Mitral Valve in Valve, MitraClip
Clinical Trials – Mitral Valve: Apollo, EVOQUE, PARTNER 3 Mitral Valve in Valve, PASCAL CLASP IID 

James D. Flaherty, MD 
 Interventional Cardiology
Commercially Available – Mitral Valve: Mitral Valve in Valve
Clinical Trials – Mitral Valve: PARTNER 3 Mitral Valve in Valve 

Mark J. Ricciardi, MD 
 Interventional Cardiology
Commercially Available – Mitral Valve: Mitral Valve in Valve, MitraClip
Clinical Trials – Mitral Valve: Apollo, EVOQUE, PARTNER 3 Mitral Valve in Valve, PASCAL CLASP IID 

Ranya N. Sweis, MD 
 Interventional Cardiology
Commercially Available – Mitral Valve: Mitral Valve in Valve
Clinical Trials – Mitral Valve: PARTNER 3 Mitral Valve in Valve 

S. Chris Malaisrie, MD 
 Cardiac Surgery
Commercially Available – Mitral Valve: Mitral Valve in Valve
Clinical Trials – Mitral Valve: Apollo, EVOQUE, PARTNER 3 Mitral Valve in Valve, PASCAL CLASP IID 

Andrei Churyla, MD 
Cardiac Surgery
Commercially Available – Mitral Valve: Mitral Valve in Valve
Clinical Trials – Mitral Valve: PARTNER 3 Mitral Valve in Valve 

Duc Thinh Pham, MD 
 Cardiac Surgery
Commercially Available – Mitral Valve: Mitral Valve in Valve
Clinical Trials – Mitral Valve: EVOQUE, PARTNER 3 Mitral Valve in Valve 

Northwestern Memorial Hospital 312.NM.HEART (312.664.3278)

Transcatheter Mitral Heart Valve Therapies: MitraClip, Now Helping More Patients 

The Transcatheter Heart Valve Program at Northwestern Medicine offers a wide variety of commercially available (FDA approved) and clinical trial options for the mitral valve, allowing us to tailor treatment precisely to each patient’s individual needs. For some patients with mitral valve disease, transcatheter heart valve therapies, like MitraClip, are an alternative treatment to open heart valve surgery. 

In 2013, the U.S. FDA approved MitraClip for patients with degenerative or primary mitral regurgitation caused by disease of the mitral valve. In 2019, results from the COAPT™ clinical trial resultsshowed that treatment with MitraClip leads to a reduction in hospitalizations and death compared to medical therapy alone. 

Transcatheter Mitral Valve Clinical Trial Options 

Researchers at Northwestern Medicine conduct clinical trials that provide access to innovative therapies for the treatment of heart and vascular disease. Participating in a clinical trial is an opportunity to evaluate the effectiveness and safety of medications or study devices. The study devices and delivery systems used in the following clinical trials are investigational (experimental), which means they are not approved for commercial use by the U.S. FDA.

MitraClip in place clipping together a portion of the mitral valve

Mitral valve in valve replacement

Patrick M. McCarthy, MD 
 Cardiac Surgery
Clinical Trials – Mitral Valve: Apollo 

Meet the Team

Bluhm Cardiovascular Institute at Northwestern Memorial Hospital
 675 N. Saint Clair Street
 Galter Pavilion, Suite 19-100
 Chicago, IL 60611
312.NM.HEART (312.664.3278)

Northwestern Medicine is also among the most experienced programs in the country for transcatheter treatment options for the aortic valve and tricuspid valve

As a result of these findings, the FDA approved MitraClip for patients with functional or secondary mitral regurgitation caused by diminished heart function. This approval has significantly expanded the number of people who can be treated with MitraClip.

As a leader in transcatheter mitral valve treatment options, Northwestern Memorial Hospital not only has one of the highest-volume MitraClip programs in Illinois3, but is also active in training physicians across the country on this and other advanced techniques.  

1. Health Status After Transcatheter Mitral Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. JACC, 2019. 
2. Health status evaluated at baseline, 1, 6, 12, and 24 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Medical Outcomes Study Short Form 36 (SF-36) Health Survey.
3. IL IP COMPdata FY16 October-FY18 June YTD, last accessed December 2018. 

  

Transcatheter Mitral Valve Commercially Available Treatment Options

Transcatheter procedures allow the procedure to be performed while the patient’s heart is still beating, eliminating the need for a “heart bypass” machine and its associated risks. Due to the minimally invasive nature of transcatheter procedures, patients tend to recover faster and experience an improvement in symptoms soon after the procedure is completed. The Transcatheter Heart Valve Program at Northwestern Medicine offers two mitral valve transcatheter treatment options: MitraClip and transcatheter mitral valve in valve replacement.

COAPTTM Clinical Trial Results1: MitraClip vs. Medical Therapy in Advanced Heart Failure Patients with Secondary or Functional Mitral Regurgitation
 
MitraClip + Medical Therapy
Medical Therapy Alone
Annualized HF hospitalizations
35.8%  (lower number is better)
67.9%
All-Cause Mortality (death)
29.1%  (lower number is better)
46.1%
Alive and Moderately Improved Quality of Life2
36.4%  (higher number is better)
16.6%
Alive and Substantially Improved Quality of Life2
29.1%  (higher number is better)
11.7%

PARTNER 3 Mitral Valve in Valve: enrolling patients who have some (intermediate) risk for undergoing open heart surgery and have an existing bioprosthetic mitral valve that is failing and needs to be replaced. Eligible participants will receive the SAPIEN 3 transcatheter heart valve (study device) to replace the failing bioprosthetic mitral valve. 

APOLLO: enrolling patients to evaluate the Intrepid Transcatheter Mitral Valve Replacement (TMVR) System (study device) in people with severe, symptomatic mitral regurgitation. Eligible participants will be randomized to receive a TMVR using the Intrepid valve, and the other group will receive traditional open heart mitral valve surgery.

EVOQUE: enrolling patients to evaluate the Edwards EVOQUE Transcatheter Mitral Valve Replacement System (study device) in high surgical risk patients with moderate to severe mitral regurgitation. The EVOQUE valve is designed to replace the mitral heart valve without open heart surgery.  

PASCAL CLASP IID: enrolling patients to evaluate the Edwards PASCAL Transcatheter Mitral Valve Repair System (PASCAL System) (study device) in patients with symptomatic degenerative mitral regurgitation who have been determined to be at prohibitive risk for mitral valve surgery. Eligible participants will be randomized to have the PASCAL System and the other group will receive the FDA-approved MitraClip System. The PASCAL System and the MitraClip System are designed to reduce the amount of mitral regurgitation without the need for surgery (less invasive).  

MitraClip: A minimally invasive treatment option for patients with mitral regurgitation. In patients with mitral regurgitation, the mitral valve does not close completely, allowing blood to flow backward or “leak,” creating symptoms that may include shortness of breath, fatigue and chest pain. MitraClip is the only device currently approved by the FDA for transcatheter mitral valve replacement (TMVR). 

During MitraClip implantation, an interventional cardiologist inserts a catheter (tube) in the body through the femoral (groin) vein. The MitraClip device is compressed and advanced by a catheter through the vein until it reaches the diseased mitral valve. Once in the heart, the MitraClip device is positioned to join or “clip” together a portion of the mitral valve, reducing or eliminating the backward flow of blood. 

Transcatheter Mitral Valve in Valve Replacement: A minimally invasive TMVR procedure for patients who have had previous open heart valve surgery to replace the mitral valve with a bioprosthetic/tissue valve and the valve is now failing. Instead of the failing mitral valve being replaced during another open heart valve surgery, the failing mitral valve is replaced by placing a TMVR valve inside the failing mitral valve. 

During mitral valve in valve replacement, an interventional cardiologist and/or a cardiac surgeon inserts a catheter (tube) through a vein in the body. The TMVR valve is compressed and advanced by a catheter through a vein until it reaches the failing mitral valve. A balloon on the catheter expands and secures the TMVR valve within the failing mitral valve. The catheter is then removed and the secured TMVR valve remains in place pushing the failing mitral tissue valve out of the way, allowing the TMVR valve to take over the job of regulating blood flow from the heart. 

We are proud of our U.S. News & World Report cardiology and heart surgery program ranking – a reflection of the leading-edge services we offer and the results we achieve for our patients, their families and the region we serve. 

  • Among the top 10 cardiology and heart surgery programs in the nation (#7) of 590 programs
  • Highest ranked cardiology and heart surgery program in Illinois, and the highest ranked program in the region including Indiana, Michigan, Wisconsin, Missouri and Iowa
  • Achieved the highest available cardiology and heart surgery patient survival score (10 out of 10)